Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2019 May 17;27(1):161–175. doi: 10.1038/s41418-019-0347-0

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© ADMC Associazione Differenziamento e Morte Cellulare 2019

Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/.

PMC Copyright notice

Fig. 4 — Neither RIP1 inactivation nor RIP3 loss affects B16 lung metastases. a Scheme of experimental procedure for luciferin-B16F10 tail vein injection model of metastasis. b Representative images of Ripk1^+/+ (RIP1 WT), Ripk1^D138N/D138N (RIP1 KI), and Ripk3^+/+ (RIP3 WT) or Ripk3^-/- (RIP3 KO) recipients following luciferin exposure on day 14. Either whole animal (upper panels) or ex vivo lung (middle panels) images were collected with corresponding light images (bottom panels). Wild-type littermates were used as controls. c Quantitation of ex vivo luciferase imaging of lungs 14 days post injection of B16F10-luciferin cell line in either Ripk1^D138N/D138N (RIP1 KI, red squares, n = 15) or Ripk3^-/- (RIP3 KO, blue squares, n = 8) recipients